In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > BUSINESS
BUSINESS
- Kissei Aims to Maintain Non-Consolidated Sales, Launch Hyperphosphatemia Treatment: New Midterm Plan
May 12, 2014
- DSP to Execute Option Rights to Codevelop Cerebral Infarction Cell Therapy in April-Sept.
May 9, 2014
- MTPC to Push Tenelia, Canaglu to Compete in Diabetes Field
May 9, 2014
- DSP Sales Up 11.5% in FY2013; Latuda, Softer Yen Eclipse Japan Dip
May 9, 2014
- MTPC Logs 8.4% Net Profit Rise, 1.6% Sales Decline
May 9, 2014
- Takeda FY2013 Sales Up 8.6% on Buoyant Azilva, Pantoprazole
May 9, 2014
- Seikagaku to Initiate PII/III Clinical Trial of SI-614 for Treatment of Dry Eye in the US
May 9, 2014
- PII Study of Transdermal Allergic Rhinitis Treatment Confirms Significant Improvement in Primary Endpoint: Hisamitsu
May 9, 2014
- Eisai Sets Up Global Oncology and Neurology Business Units Ahead of Schedule
May 8, 2014
- Eisai Moves to Boost Global Use of Products via Emerging Market Businesses
May 8, 2014
- Suglat Tops Anterio’s "Mind Share" Ranking in GP Market in March; Xarelto Rises Sharply
May 8, 2014
- FDA Grants Priority Review to XTANDI for Add’l Indication: Astellas
May 8, 2014
- Takara Bio Submits IND Application for PII Study of Anticancer Agent HF10 to US FDA
May 8, 2014
- Drug Information Gained Mostly from Sales Reps, Less from Online Promotion: IMS Survey
May 8, 2014
- Nitto Denko Moving Ahead at Full Speed in Japan, US to Develop Nucleic Acid Drug as a Potential Cure for Cirrhosis
May 7, 2014
- Announcement: 1st Annual Real World Data Japan 2014 - Tokyo Marriott Hotel, July 15-16
May 7, 2014
- Drug Makers’ Plans for MRs Becoming Clearer; Takeda to Bolster Force, Sanofi Making Big Reduction
May 7, 2014
- Ono, Nissan Chemical End Licensing Deal on Thrombocytopenia Agent
May 2, 2014
- Otsuka Granted European Approval for Multidrug-Resistant TB Medicine
May 2, 2014
- Oncolys Obtains Patent on Manufacturing Process for Anti-HIV Drug OBP-601 in Japan
May 2, 2014
ページ
An increasing number of companies in Japan are showing an eagerness to snatch up “drug loss” assets. As of this…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…